nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Epirubicin—peripheral nervous system neoplasm	0.413	0.809	CbGbCtD
Orlistat—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0322	0.0632	CbGbCtD
Orlistat—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0299	0.0588	CbGbCtD
Orlistat—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0138	0.027	CbGbCtD
Orlistat—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0126	0.0247	CbGbCtD
Orlistat—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00859	0.0169	CbGbCtD
Orlistat—FASN—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.0074	1	CbGdCrCtD
Orlistat—ABHD16A—trigeminal ganglion—peripheral nervous system neoplasm	0.00299	0.135	CbGeAlD
Orlistat—ABHD16A—parotid gland—peripheral nervous system neoplasm	0.00282	0.127	CbGeAlD
Orlistat—ABHD12—trigeminal ganglion—peripheral nervous system neoplasm	0.0028	0.126	CbGeAlD
Orlistat—ABHD12—parotid gland—peripheral nervous system neoplasm	0.00264	0.119	CbGeAlD
Orlistat—FASN—trigeminal ganglion—peripheral nervous system neoplasm	0.00235	0.106	CbGeAlD
Orlistat—DAGLA—cerebellum—peripheral nervous system neoplasm	0.00222	0.0999	CbGeAlD
Orlistat—DAGLB—cerebellum—peripheral nervous system neoplasm	0.00172	0.0774	CbGeAlD
Orlistat—ABHD16A—cerebellum—peripheral nervous system neoplasm	0.0013	0.0587	CbGeAlD
Orlistat—ABHD12—cerebellum—peripheral nervous system neoplasm	0.00122	0.055	CbGeAlD
Orlistat—PLA2G4A—trigeminal ganglion—peripheral nervous system neoplasm	0.00113	0.0508	CbGeAlD
Orlistat—FASN—cerebellum—peripheral nervous system neoplasm	0.00103	0.0462	CbGeAlD
Orlistat—DAGLA—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000654	0.00428	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000654	0.00428	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000627	0.0041	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000627	0.0041	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000617	0.00404	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000617	0.00404	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—PTPN11—peripheral nervous system neoplasm	0.000609	0.00398	CbGpPWpGaD
Orlistat—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000606	0.00397	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—BCHE—peripheral nervous system neoplasm	0.000606	0.00396	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000599	0.00392	CbGpPWpGaD
Orlistat—PLA2G4A—Glycerophospholipid biosynthesis—BCHE—peripheral nervous system neoplasm	0.000595	0.00389	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000555	0.00363	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000553	0.00361	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000553	0.00361	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000546	0.00357	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000546	0.00357	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00053	0.00346	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000512	0.00335	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000512	0.00335	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet homeostasis—GNAS—peripheral nervous system neoplasm	0.000503	0.00329	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000496	0.00324	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000496	0.00324	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000458	0.00299	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000458	0.00299	CbGpPWpGaD
Orlistat—PNLIP—Disease—GNS—peripheral nervous system neoplasm	0.000457	0.00299	CbGpPWpGaD
Orlistat—FASN—p73 transcription factor network—MYC—peripheral nervous system neoplasm	0.000452	0.00295	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000448	0.00293	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000448	0.00293	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.00044	0.00288	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HGF—peripheral nervous system neoplasm	0.000427	0.00279	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HGF—peripheral nervous system neoplasm	0.000427	0.00279	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PTPN11—peripheral nervous system neoplasm	0.000425	0.00278	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—BCHE—peripheral nervous system neoplasm	0.000415	0.00271	CbGpPWpGaD
Orlistat—FASN—AMPK Signaling—TP53—peripheral nervous system neoplasm	0.000413	0.0027	CbGpPWpGaD
Orlistat—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000391	0.00256	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000386	0.00253	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000386	0.00253	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GNS—peripheral nervous system neoplasm	0.000383	0.0025	CbGpPWpGaD
Orlistat—PLA2G4A—p38 MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	0.00038	0.00249	CbGpPWpGaD
Orlistat—FASN—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000375	0.00245	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000371	0.00243	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000371	0.00243	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000371	0.00242	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000371	0.00242	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NME1—peripheral nervous system neoplasm	0.000367	0.0024	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000361	0.00236	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—COX2—peripheral nervous system neoplasm	0.000353	0.00231	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet homeostasis—PTPN11—peripheral nervous system neoplasm	0.00035	0.00229	CbGpPWpGaD
Orlistat—FASN—AMPK Signaling—AKT1—peripheral nervous system neoplasm	0.000349	0.00228	CbGpPWpGaD
Orlistat—FASN—SREBP signalling—AKT1—peripheral nervous system neoplasm	0.000349	0.00228	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000324	0.00212	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000324	0.00212	CbGpPWpGaD
Orlistat—FASN—Disease—GNS—peripheral nervous system neoplasm	0.000324	0.00212	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00032	0.00209	CbGpPWpGaD
Orlistat—PNLIP—Disease—PPP3R1—peripheral nervous system neoplasm	0.00032	0.00209	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000311	0.00204	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000311	0.00204	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000311	0.00204	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000307	0.00201	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	0.000305	0.002	CbGpPWpGaD
Orlistat—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000299	0.00195	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000294	0.00192	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000294	0.00192	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000294	0.00192	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000293	0.00192	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000293	0.00192	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—CASP3—peripheral nervous system neoplasm	0.000287	0.00187	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000283	0.00185	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000283	0.00185	CbGpPWpGaD
Orlistat—PNLIP—Disease—ENO2—peripheral nervous system neoplasm	0.000277	0.00181	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000272	0.00178	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000272	0.00178	CbGpPWpGaD
Orlistat—FASN—Metabolism—GNS—peripheral nervous system neoplasm	0.000271	0.00177	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00027	0.00177	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00027	0.00177	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000268	0.00175	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—HRAS—peripheral nervous system neoplasm	0.000268	0.00175	CbGpPWpGaD
Orlistat—FASN—Metabolism—NME1—peripheral nervous system neoplasm	0.00026	0.0017	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000257	0.00168	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000257	0.00168	CbGpPWpGaD
Orlistat—FASN—Metabolism—COX2—peripheral nervous system neoplasm	0.00025	0.00164	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.00025	0.00163	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000245	0.0016	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000243	0.00159	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000241	0.00158	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—PTPN11—peripheral nervous system neoplasm	0.00024	0.00157	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000238	0.00156	CbGpPWpGaD
Orlistat—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000236	0.00154	CbGpPWpGaD
Orlistat—Rash—Topotecan—peripheral nervous system neoplasm	0.000235	0.000765	CcSEcCtD
Orlistat—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000235	0.000764	CcSEcCtD
Orlistat—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000235	0.000764	CcSEcCtD
Orlistat—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000235	0.000762	CcSEcCtD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	0.000235	0.00153	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	0.000235	0.00153	CbGpPWpGaD
Orlistat—Cough—Etoposide—peripheral nervous system neoplasm	0.000234	0.000761	CcSEcCtD
Orlistat—Headache—Topotecan—peripheral nervous system neoplasm	0.000234	0.00076	CcSEcCtD
Orlistat—Rash—Tretinoin—peripheral nervous system neoplasm	0.000234	0.000759	CcSEcCtD
Orlistat—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000234	0.000759	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000234	0.000759	CcSEcCtD
Orlistat—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000233	0.000758	CcSEcCtD
Orlistat—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000233	0.000758	CcSEcCtD
Orlistat—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000233	0.000758	CcSEcCtD
Orlistat—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000233	0.000756	CcSEcCtD
Orlistat—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000232	0.000756	CcSEcCtD
Orlistat—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000232	0.000755	CcSEcCtD
Orlistat—Headache—Tretinoin—peripheral nervous system neoplasm	0.000232	0.000754	CcSEcCtD
Orlistat—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000232	0.000754	CcSEcCtD
Orlistat—PNLIP—Metabolism—ENO2—peripheral nervous system neoplasm	0.000232	0.00152	CbGpPWpGaD
Orlistat—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000231	0.000752	CcSEcCtD
Orlistat—Pain—Vincristine—peripheral nervous system neoplasm	0.000231	0.000752	CcSEcCtD
Orlistat—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000752	CcSEcCtD
Orlistat—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000231	0.000752	CcSEcCtD
Orlistat—Rash—Melphalan—peripheral nervous system neoplasm	0.000231	0.000749	CcSEcCtD
Orlistat—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00023	0.000749	CcSEcCtD
Orlistat—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00023	0.000746	CcSEcCtD
Orlistat—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000745	CcSEcCtD
Orlistat—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000229	0.000743	CcSEcCtD
Orlistat—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000742	CcSEcCtD
Orlistat—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000739	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000227	0.000738	CcSEcCtD
Orlistat—FASN—Disease—PPP3R1—peripheral nervous system neoplasm	0.000226	0.00148	CbGpPWpGaD
Orlistat—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000226	0.000734	CcSEcCtD
Orlistat—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000734	CcSEcCtD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000225	0.00147	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000224	0.00146	CbGpPWpGaD
Orlistat—PNLIP—Disease—SLC2A1—peripheral nervous system neoplasm	0.000223	0.00146	CbGpPWpGaD
Orlistat—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000223	0.000725	CcSEcCtD
Orlistat—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000223	0.000725	CcSEcCtD
Orlistat—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000222	0.000721	CcSEcCtD
Orlistat—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000222	0.000721	CcSEcCtD
Orlistat—Nausea—Topotecan—peripheral nervous system neoplasm	0.000222	0.000721	CcSEcCtD
Orlistat—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000221	0.000719	CcSEcCtD
Orlistat—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000719	CcSEcCtD
Orlistat—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00022	0.000715	CcSEcCtD
Orlistat—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00022	0.000715	CcSEcCtD
Orlistat—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000219	0.000712	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000218	0.000708	CcSEcCtD
Orlistat—Infection—Etoposide—peripheral nervous system neoplasm	0.000218	0.000708	CcSEcCtD
Orlistat—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000217	0.000707	CcSEcCtD
Orlistat—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000217	0.000706	CcSEcCtD
Orlistat—Nausea—Melphalan—peripheral nervous system neoplasm	0.000217	0.000706	CcSEcCtD
Orlistat—Asthma—Epirubicin—peripheral nervous system neoplasm	0.000216	0.000702	CcSEcCtD
Orlistat—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000216	0.000702	CcSEcCtD
Orlistat—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000215	0.000698	CcSEcCtD
Orlistat—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000214	0.000695	CcSEcCtD
Orlistat—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000214	0.000695	CcSEcCtD
Orlistat—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000213	0.000692	CcSEcCtD
Orlistat—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000689	CcSEcCtD
Orlistat—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000212	0.000688	CcSEcCtD
Orlistat—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000688	CcSEcCtD
Orlistat—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000686	CcSEcCtD
Orlistat—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000684	CcSEcCtD
Orlistat—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000679	CcSEcCtD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000208	0.00136	CbGpPWpGaD
Orlistat—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000208	0.000676	CcSEcCtD
Orlistat—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000207	0.000673	CcSEcCtD
Orlistat—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000207	0.000672	CcSEcCtD
Orlistat—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000207	0.000671	CcSEcCtD
Orlistat—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000665	CcSEcCtD
Orlistat—Pain—Cisplatin—peripheral nervous system neoplasm	0.000205	0.000665	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000203	0.00133	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000203	0.00133	CbGpPWpGaD
Orlistat—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000201	0.000655	CcSEcCtD
Orlistat—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.000654	CcSEcCtD
Orlistat—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000652	CcSEcCtD
Orlistat—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.00065	CcSEcCtD
Orlistat—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.00065	CcSEcCtD
Orlistat—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000199	0.000648	CcSEcCtD
Orlistat—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000199	0.000645	CcSEcCtD
Orlistat—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000197	0.000641	CcSEcCtD
Orlistat—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000197	0.000639	CcSEcCtD
Orlistat—PNLIP—Metabolism—BCHE—peripheral nervous system neoplasm	0.000196	0.00128	CbGpPWpGaD
Orlistat—FASN—Disease—ENO2—peripheral nervous system neoplasm	0.000196	0.00128	CbGpPWpGaD
Orlistat—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000637	CcSEcCtD
Orlistat—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000194	0.000631	CcSEcCtD
Orlistat—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000626	CcSEcCtD
Orlistat—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000626	CcSEcCtD
Orlistat—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000193	0.000626	CcSEcCtD
Orlistat—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000192	0.000624	CcSEcCtD
Orlistat—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000191	0.00062	CcSEcCtD
Orlistat—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000191	0.000619	CcSEcCtD
Orlistat—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000615	CcSEcCtD
Orlistat—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000189	0.000615	CcSEcCtD
Orlistat—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000189	0.000615	CcSEcCtD
Orlistat—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000189	0.000614	CcSEcCtD
Orlistat—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000614	CcSEcCtD
Orlistat—Pain—Etoposide—peripheral nervous system neoplasm	0.000187	0.000609	CcSEcCtD
Orlistat—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000187	0.000608	CcSEcCtD
Orlistat—DAGLA—Hemostasis—NRAS—peripheral nervous system neoplasm	0.000187	0.00122	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—NRAS—peripheral nervous system neoplasm	0.000187	0.00122	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—peripheral nervous system neoplasm	0.000187	0.00122	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000187	0.00122	CbGpPWpGaD
Orlistat—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000604	CcSEcCtD
Orlistat—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000186	0.000603	CcSEcCtD
Orlistat—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000185	0.000602	CcSEcCtD
Orlistat—PNLIP—Metabolism—TH—peripheral nervous system neoplasm	0.000184	0.00121	CbGpPWpGaD
Orlistat—PLA2G4A—Endothelins—HRAS—peripheral nervous system neoplasm	0.000182	0.00119	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000592	CcSEcCtD
Orlistat—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000587	CcSEcCtD
Orlistat—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000181	0.000587	CcSEcCtD
Orlistat—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00018	0.000584	CcSEcCtD
Orlistat—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000179	0.000582	CcSEcCtD
Orlistat—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000179	0.000581	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000179	0.00117	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000179	0.00117	CbGpPWpGaD
Orlistat—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000179	0.00058	CcSEcCtD
Orlistat—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000579	CcSEcCtD
Orlistat—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000579	CcSEcCtD
Orlistat—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000177	0.000575	CcSEcCtD
Orlistat—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000177	0.000575	CcSEcCtD
Orlistat—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000176	0.000573	CcSEcCtD
Orlistat—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000176	0.000572	CcSEcCtD
Orlistat—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000569	CcSEcCtD
Orlistat—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000568	CcSEcCtD
Orlistat—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000174	0.000566	CcSEcCtD
Orlistat—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000565	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000174	0.00114	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000174	0.00114	CbGpPWpGaD
Orlistat—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000173	0.000563	CcSEcCtD
Orlistat—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000173	0.000563	CcSEcCtD
Orlistat—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000563	CcSEcCtD
Orlistat—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000562	CcSEcCtD
Orlistat—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000562	CcSEcCtD
Orlistat—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000172	0.000559	CcSEcCtD
Orlistat—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000172	0.000558	CcSEcCtD
Orlistat—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000558	CcSEcCtD
Orlistat—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000555	CcSEcCtD
Orlistat—Rash—Vincristine—peripheral nervous system neoplasm	0.000171	0.000554	CcSEcCtD
Orlistat—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00017	0.000554	CcSEcCtD
Orlistat—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000554	CcSEcCtD
Orlistat—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000551	CcSEcCtD
Orlistat—Headache—Vincristine—peripheral nervous system neoplasm	0.000169	0.000551	CcSEcCtD
Orlistat—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000548	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000168	0.0011	CbGpPWpGaD
Orlistat—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000543	CcSEcCtD
Orlistat—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000167	0.000542	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000166	0.00108	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000166	0.00108	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—AKT1—peripheral nervous system neoplasm	0.000165	0.00108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000165	0.00108	CbGpPWpGaD
Orlistat—FASN—Metabolism—ENO2—peripheral nervous system neoplasm	0.000164	0.00107	CbGpPWpGaD
Orlistat—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000164	0.000532	CcSEcCtD
Orlistat—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000161	0.000525	CcSEcCtD
Orlistat—PLA2G4A—Endothelins—AKT1—peripheral nervous system neoplasm	0.000161	0.00105	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000161	0.00105	CbGpPWpGaD
Orlistat—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000523	CcSEcCtD
Orlistat—Nausea—Vincristine—peripheral nervous system neoplasm	0.000161	0.000522	CcSEcCtD
Orlistat—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.00052	CcSEcCtD
Orlistat—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.00052	CcSEcCtD
Orlistat—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000516	CcSEcCtD
Orlistat—FASN—Disease—SLC2A1—peripheral nervous system neoplasm	0.000158	0.00103	CbGpPWpGaD
Orlistat—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000513	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000158	0.00103	CbGpPWpGaD
Orlistat—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000512	CcSEcCtD
Orlistat—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000157	0.000511	CcSEcCtD
Orlistat—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.00051	CcSEcCtD
Orlistat—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000508	CcSEcCtD
Orlistat—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000506	CcSEcCtD
Orlistat—PLA2G4A—AGE/RAGE pathway—AKT1—peripheral nervous system neoplasm	0.000155	0.00101	CbGpPWpGaD
Orlistat—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000155	0.000504	CcSEcCtD
Orlistat—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000153	0.000497	CcSEcCtD
Orlistat—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000152	0.000494	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000152	0.000993	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000152	0.000993	CbGpPWpGaD
Orlistat—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000492	CcSEcCtD
Orlistat—Rash—Cisplatin—peripheral nervous system neoplasm	0.000151	0.00049	CcSEcCtD
Orlistat—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000151	0.00049	CcSEcCtD
Orlistat—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000489	CcSEcCtD
Orlistat—PNLIP—Metabolism—GNAS—peripheral nervous system neoplasm	0.00015	0.000984	CbGpPWpGaD
Orlistat—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00015	0.000487	CcSEcCtD
Orlistat—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000482	CcSEcCtD
Orlistat—PNLIP—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000148	0.000966	CbGpPWpGaD
Orlistat—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000479	CcSEcCtD
Orlistat—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000473	CcSEcCtD
Orlistat—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000145	0.000471	CcSEcCtD
Orlistat—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000145	0.00047	CcSEcCtD
Orlistat—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.00047	CcSEcCtD
Orlistat—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000469	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—NRAS—peripheral nervous system neoplasm	0.000144	0.000942	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000144	0.000941	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—peripheral nervous system neoplasm	0.000143	0.000936	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—TP53—peripheral nervous system neoplasm	0.000143	0.000936	CbGpPWpGaD
Orlistat—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000142	0.000462	CcSEcCtD
Orlistat—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000461	CcSEcCtD
Orlistat—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000459	CcSEcCtD
Orlistat—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000455	CcSEcCtD
Orlistat—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000454	CcSEcCtD
Orlistat—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000139	0.000453	CcSEcCtD
Orlistat—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000453	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000139	0.000909	CbGpPWpGaD
Orlistat—FASN—Metabolism—BCHE—peripheral nervous system neoplasm	0.000139	0.000907	CbGpPWpGaD
Orlistat—Rash—Etoposide—peripheral nervous system neoplasm	0.000138	0.000449	CcSEcCtD
Orlistat—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000138	0.000449	CcSEcCtD
Orlistat—Headache—Etoposide—peripheral nervous system neoplasm	0.000137	0.000446	CcSEcCtD
Orlistat—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000446	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000137	0.000897	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000137	0.000895	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000137	0.000895	CbGpPWpGaD
Orlistat—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000443	CcSEcCtD
Orlistat—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000441	CcSEcCtD
Orlistat—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000439	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000135	0.000882	CbGpPWpGaD
Orlistat—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000438	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—MYC—peripheral nervous system neoplasm	0.000134	0.000878	CbGpPWpGaD
Orlistat—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000435	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000134	0.000874	CbGpPWpGaD
Orlistat—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000432	CcSEcCtD
Orlistat—FASN—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000132	0.000865	CbGpPWpGaD
Orlistat—Cough—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000427	CcSEcCtD
Orlistat—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000427	CcSEcCtD
Orlistat—FASN—Metabolism—TH—peripheral nervous system neoplasm	0.00013	0.000853	CbGpPWpGaD
Orlistat—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000424	CcSEcCtD
Orlistat—Nausea—Etoposide—peripheral nervous system neoplasm	0.00013	0.000423	CcSEcCtD
Orlistat—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.00042	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000129	0.000843	CbGpPWpGaD
Orlistat—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000416	CcSEcCtD
Orlistat—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000416	CcSEcCtD
Orlistat—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000415	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000414	CcSEcCtD
Orlistat—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000411	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000126	0.000823	CbGpPWpGaD
Orlistat—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000408	CcSEcCtD
Orlistat—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000407	CcSEcCtD
Orlistat—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000407	CcSEcCtD
Orlistat—PNLIP—Disease—PTPN11—peripheral nervous system neoplasm	0.000125	0.000817	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000125	0.000816	CbGpPWpGaD
Orlistat—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.0004	CcSEcCtD
Orlistat—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000399	CcSEcCtD
Orlistat—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000399	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000122	0.000801	CbGpPWpGaD
Orlistat—Infection—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000397	CcSEcCtD
Orlistat—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000395	CcSEcCtD
Orlistat—DAGLB—Hemostasis—AKT1—peripheral nervous system neoplasm	0.000121	0.000791	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—AKT1—peripheral nervous system neoplasm	0.000121	0.000791	CbGpPWpGaD
Orlistat—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000392	CcSEcCtD
Orlistat—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000391	CcSEcCtD
Orlistat—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000388	CcSEcCtD
Orlistat—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000386	CcSEcCtD
Orlistat—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000385	CcSEcCtD
Orlistat—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000385	CcSEcCtD
Orlistat—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000384	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000383	CcSEcCtD
Orlistat—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000381	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—GNS—peripheral nervous system neoplasm	0.000116	0.00076	CbGpPWpGaD
Orlistat—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000377	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000115	0.000753	CbGpPWpGaD
Orlistat—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000369	CcSEcCtD
Orlistat—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000369	CcSEcCtD
Orlistat—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000367	CcSEcCtD
Orlistat—PLA2G4A—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000113	0.000737	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000364	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—NME1—peripheral nervous system neoplasm	0.000111	0.000729	CbGpPWpGaD
Orlistat—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000362	CcSEcCtD
Orlistat—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000361	CcSEcCtD
Orlistat—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000359	CcSEcCtD
Orlistat—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000358	CcSEcCtD
Orlistat—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000357	CcSEcCtD
Orlistat—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000351	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000107	0.000702	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000107	0.000702	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HGF—peripheral nervous system neoplasm	0.000107	0.000702	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—COX2—peripheral nervous system neoplasm	0.000107	0.000702	CbGpPWpGaD
Orlistat—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000347	CcSEcCtD
Orlistat—FASN—Metabolism—GNAS—peripheral nervous system neoplasm	0.000106	0.000696	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000345	CcSEcCtD
Orlistat—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000344	CcSEcCtD
Orlistat—DAGLA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000106	0.00069	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000106	0.00069	CbGpPWpGaD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	0.000105	0.000689	CbGpPWpGaD
Orlistat—Pain—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000341	CcSEcCtD
Orlistat—FASN—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000104	0.000683	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000337	CcSEcCtD
Orlistat—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000334	CcSEcCtD
Orlistat—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000332	CcSEcCtD
Orlistat—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000329	CcSEcCtD
Orlistat—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000326	CcSEcCtD
Orlistat—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000325	CcSEcCtD
Orlistat—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	9.88e-05	0.000321	CcSEcCtD
Orlistat—PNLIP—Disease—ERBB2—peripheral nervous system neoplasm	9.87e-05	0.000645	CbGpPWpGaD
Orlistat—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	9.81e-05	0.000319	CcSEcCtD
Orlistat—Fatigue—Doxorubicin—peripheral nervous system neoplasm	9.8e-05	0.000318	CcSEcCtD
Orlistat—Urticaria—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000317	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.72e-05	0.000636	CbGpPWpGaD
Orlistat—Pain—Doxorubicin—peripheral nervous system neoplasm	9.72e-05	0.000316	CcSEcCtD
Orlistat—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	9.71e-05	0.000316	CcSEcCtD
Orlistat—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	9.71e-05	0.000316	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	9.56e-05	0.000625	CbGpPWpGaD
Orlistat—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	9.37e-05	0.000304	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.32e-05	0.00061	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	9.29e-05	0.000302	CcSEcCtD
Orlistat—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	9.05e-05	0.000294	CcSEcCtD
Orlistat—Urticaria—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000293	CcSEcCtD
Orlistat—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000292	CcSEcCtD
Orlistat—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000292	CcSEcCtD
Orlistat—FASN—Disease—PTPN11—peripheral nervous system neoplasm	8.83e-05	0.000578	CbGpPWpGaD
Orlistat—Asthenia—Epirubicin—peripheral nervous system neoplasm	8.81e-05	0.000286	CcSEcCtD
Orlistat—PNLIP—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.74e-05	0.000572	CbGpPWpGaD
Orlistat—Pruritus—Epirubicin—peripheral nervous system neoplasm	8.69e-05	0.000282	CcSEcCtD
Orlistat—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	8.41e-05	0.000273	CcSEcCtD
Orlistat—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	8.37e-05	0.000272	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.34e-05	0.000545	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.34e-05	0.000545	CbGpPWpGaD
Orlistat—Asthenia—Doxorubicin—peripheral nervous system neoplasm	8.16e-05	0.000265	CcSEcCtD
Orlistat—Dizziness—Epirubicin—peripheral nervous system neoplasm	8.12e-05	0.000264	CcSEcCtD
Orlistat—Pruritus—Doxorubicin—peripheral nervous system neoplasm	8.04e-05	0.000261	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.86e-05	0.000514	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.86e-05	0.000514	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	7.85e-05	0.000514	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PTPN11—peripheral nervous system neoplasm	7.83e-05	0.000512	CbGpPWpGaD
Orlistat—Vomiting—Epirubicin—peripheral nervous system neoplasm	7.81e-05	0.000254	CcSEcCtD
Orlistat—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	7.78e-05	0.000253	CcSEcCtD
Orlistat—Rash—Epirubicin—peripheral nervous system neoplasm	7.75e-05	0.000252	CcSEcCtD
Orlistat—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.74e-05	0.000251	CcSEcCtD
Orlistat—Headache—Epirubicin—peripheral nervous system neoplasm	7.7e-05	0.00025	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.64e-05	0.0005	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.64e-05	0.0005	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.57e-05	0.000495	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.57e-05	0.000495	CbGpPWpGaD
Orlistat—Dizziness—Doxorubicin—peripheral nervous system neoplasm	7.52e-05	0.000244	CcSEcCtD
Orlistat—PNLIP—Disease—NRAS—peripheral nervous system neoplasm	7.51e-05	0.000491	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.4e-05	0.000484	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.37e-05	0.000482	CbGpPWpGaD
Orlistat—Nausea—Epirubicin—peripheral nervous system neoplasm	7.3e-05	0.000237	CcSEcCtD
Orlistat—Vomiting—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000235	CcSEcCtD
Orlistat—Rash—Doxorubicin—peripheral nervous system neoplasm	7.17e-05	0.000233	CcSEcCtD
Orlistat—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	7.16e-05	0.000233	CcSEcCtD
Orlistat—Headache—Doxorubicin—peripheral nervous system neoplasm	7.12e-05	0.000231	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—ENO2—peripheral nervous system neoplasm	7.05e-05	0.000461	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—peripheral nervous system neoplasm	6.99e-05	0.000457	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—peripheral nervous system neoplasm	6.98e-05	0.000457	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.94e-05	0.000454	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.94e-05	0.000454	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.91e-05	0.000452	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.8e-05	0.000445	CbGpPWpGaD
Orlistat—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.75e-05	0.000219	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.63e-05	0.000434	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.47e-05	0.000423	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.35e-05	0.000415	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.35e-05	0.000415	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.27e-05	0.00041	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—BCHE—peripheral nervous system neoplasm	5.95e-05	0.000389	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.91e-05	0.000386	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.91e-05	0.000386	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	5.9e-05	0.000386	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.68e-05	0.000371	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TH—peripheral nervous system neoplasm	5.6e-05	0.000366	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.58e-05	0.000365	CbGpPWpGaD
Orlistat—PNLIP—Disease—HRAS—peripheral nervous system neoplasm	5.49e-05	0.000359	CbGpPWpGaD
Orlistat—FASN—Disease—NRAS—peripheral nervous system neoplasm	5.31e-05	0.000347	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.26e-05	0.000344	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.11e-05	0.000334	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—peripheral nervous system neoplasm	4.95e-05	0.000324	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.9e-05	0.00032	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.85e-05	0.000317	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.85e-05	0.000317	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—peripheral nervous system neoplasm	4.85e-05	0.000317	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NRAS—peripheral nervous system neoplasm	4.71e-05	0.000308	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.64e-05	0.000304	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.64e-05	0.000304	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GNAS—peripheral nervous system neoplasm	4.57e-05	0.000299	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.49e-05	0.000294	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ABCB1—peripheral nervous system neoplasm	4.48e-05	0.000293	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.37e-05	0.000286	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.16e-05	0.000272	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.1e-05	0.000268	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.1e-05	0.000268	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—peripheral nervous system neoplasm	4.06e-05	0.000266	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.02e-05	0.000263	CbGpPWpGaD
Orlistat—FASN—Disease—HRAS—peripheral nervous system neoplasm	3.89e-05	0.000254	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.85e-05	0.000252	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.82e-05	0.00025	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.77e-05	0.000246	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—peripheral nervous system neoplasm	3.6e-05	0.000236	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—HRAS—peripheral nervous system neoplasm	3.44e-05	0.000225	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—peripheral nervous system neoplasm	3.43e-05	0.000224	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.4e-05	0.000222	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—peripheral nervous system neoplasm	3.04e-05	0.000199	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—peripheral nervous system neoplasm	2.87e-05	0.000188	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.72e-05	0.000178	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.7e-05	0.000177	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.65e-05	0.000174	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.61e-05	0.000171	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.51e-05	0.000164	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.1e-05	0.000137	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.98e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.9e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.75e-05	0.000114	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.65e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.6e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.49e-05	9.72e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.39e-05	9.12e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.33e-05	8.7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.31e-05	8.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—peripheral nervous system neoplasm	1.23e-05	8.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.22e-05	7.99e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.17e-05	7.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.07e-05	7e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.05e-05	6.87e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.03e-05	6.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.89e-06	1.89e-05	CbGpPWpGaD
